Three months have passed since generic versions of the SGLT-2 inhibitor class diabetes treatment ‘Forxiga (dapaglifloin)’ were released en masse in Korea. Despite the release, the original product had successfully defended its lead, increasing outpatient prescriptions.

The generic companies raised a combined prescription performance of KRW 5.9 billion in the first quarter after their release, increasing their influence to 18% of the total market. However, as more than 60 companies that have entered the competition, the average prescription performance per company was less than KRW 100 million.

Despite entry of a large number of generics...Prescriptions of Forxiga, Xigduo ris

Kim, Jin-Gu(kjg@dailypharm.com)